TABLE 1.

Characteristics of HIV-1-infected patients receiving HAART

Patient and sampleTime (days)a of:No. of CD4+ cells/mm3No. of HIV-1 RNA copies/ml of plasmab
SamplingHAART initiationSeroconversion
19062
    I6445238,900
    II729860<50 (20)
    III954986<50 (12)
    IV1,4581,002<50 (31)
212141
    I41702492,000
    II1,051842<50 (20)
    III1,235815<50 (8)
    IV1,751788<50 (7)
37958
    I7877722,200
    II4251,423<50 (25)
    III7391,518<50 (14)
    IV1,1531,265<50 (6)
42030
    I103813,500,000
    II423928<50 (30)
    III1,251841<50 (12)
51818
    I187556,000,000
    II5781,061<50 (14)
    III9411,001<50 (17)
68060
    I3543567,862
    II820718<50 (18)
    III1,017848<50 (10)
    IV1,202803<50 (11)
72120
    I2068012,500
    II485729<50 (4)
    III725801<50 (4)
    IV1,205832<50 (5)
  • a Days after the onset of acute syndrome of HIV infection (3, 44).

  • b Levels of plasma viral RNA were measured by a commercial RT-PCR assay (Amplicor ultrasensitive HIV-1 monitor assay; Roche) (3, 44). Numbers in parentheses are levels of virion RNA determined by a sensitive limiting-dilution RT-PCR (see Materials and Methods).